iData’s report on the global central venous catheter (CVC) market includes both acute and chronic CVC’s. In the past, the central venous catheter market suffered extreme consequences after the Joint Commission guidelines recommended that catheters should only be placed in the femoral vein if no other sites are available. This recommendation was due to the fact that CVCs have been known to cause Catheter-related bloodstream infections (CRBIs), depending on the insertion vein. Despite this, the global central venous catheter market is growing and is expected to reach approximately $860 million by 2026. Throughout this blog, we provide answers to two main questions:
What does the future have in store for central venous catheters?
What are some of the significant trends per region?
1 – NORTH AMERICA
Growth within the central venous catheter market in North America has been steady over the last few years. An increase in the acute CVC market is expected to apply upward pressure to the value of the total CVC market over the forecast period. Furthermore, the largest market segment is in fact the acute CVC segment, which represents the vast majority of the total CVC market. Moving into 2026, iData’s analysts predict that with the increases in unit sales, coupled with appreciating average selling prices (ASPs), the overall central venous catheter market in North America will experience growth.
2 – LATIN AMERICA
Similar to the North American market, the central venous catheter market in Latin America has been steadily growing and at a slightly higher CAGR. The CVC market growth in Latin America seems to be consistently hampered by the high risk and severity of infections associated with the use of CVCs. Alternatives such as PICCs have become more popular and have pushed CVCs, specifically chronic CVCs, to the side. Over the past few years, the ASP of chronic CVC’s in Latin America have been decreasing. Due to the risks that chronic central venous catheters cause patients, the prices for these devices are expected to continue to decrease into 2026.
3 – EUROPE
Overall, the central venous catheter market in Europe is growing at a low rate. The acute CVC market is expected to grow slightly over the forecast period. Growth within the acute CVC segment will be driven by the increasing use of antimicrobial CVCs for high-risk patients. These devices sell at a slight premium over conventional devices, and the conversion to antimicrobial CVCs will lead to growth in the market value. Despite growth within the acute CVC segment, the overall central venous catheter market, and the ASPs, in Europe are to remain relatively flat into 2026.
4 – MIDDLE EAST
By 2026, the central venous catheter market in the Middle East will increase at a seemingly stable rate. The shift towards acute CVCs, driven by increasing physician desire to minimize complications associated with chronic CVCs, is one major trend in the Middle East. Due to this market shift towards acute CVCs, total unit sales are expected to increase with modest declines in the sales of the chronic CVCs. In terms of the total central venous catheter market in the Middle East, iData’s analysts predict that the ASP will decline over the forecast period, causing the CAGR to decrease slightly towards 2026.
5 – AFRICA
As the political situation in Africa stabilizes and healthcare coverage expands, the market for central venous catheters is increasing. Despite this, the total CVC market in Africa is young and the market value is much lower than the other global regions. Shifts in preference towards acute CVCs and away from chronic CVCs is occurring. Additionally, many physicians in Africa are placing greater emphasis on proper technique and adherence to best practices to reduce infection rates, as opposed to paying more for an advanced device or kit. iData’s analysts expect that this will counteract the complete conversion to premium-priced CVCs.
6 – ASIA-PACIFIC
Central venous catheters within the Asia-Pacific region are showing indicative signs of growth into 2026. As expected, acute CVCs were the largest segment, and this is to continue. Within Asia-Pacific, the market value of the acute CVC segment will be limited by mild declines in the average selling price. iData’s analysts suspect that the depreciation in the ASP will be limited by the increasing penetration rate of premium-priced catheters and kits. While the reduction in the ASP inhibits growth over time, the total unit growth is to remain positive and continue increasing at a healthy rate.
FURTHER GLOBAL MARKET INSIGHTS
iData’s MedCore report breaks down each global central venous catheter market segment and includes market overviews and forecasts, drivers and limiters, competitive market share analysis, and more. If you’re curious to know what else the future has in store for this market, follow the link below.
